Rheumatoid Arthritis Drugs Market Growth, Size, Trends, Share, Revenue and Future Outlook
Rheumatoid Arthritis Drugs Market Size– By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Apr-2024 | Report ID: PHAR2406 | Pages: 1 - 234 | Formats*: |
| Category : Pharmaceutical | |||
Rheumatoid Arthritis Drugs Market Introduction and Overview
According to SPER Market Research, the Global Rheumatoid Arthritis Drugs Market is estimated to reach USD 78718.42 million by 2033 with a CAGR of 3.8%.
The report includes an in-depth analysis of the Global Rheumatoid Arthritis Drugs Market, including market size and trends, product mix, Applications, and supplier analysis. An autoimmune condition that causes the body's immune system to target its own tissues, including joints, is known as rheumatoid arthritis. Painful joint stiffness and edema result from this. An anti-rheumatic medicine is a pharmaceutical used to treat rheumatoid arthritis. It is a condition that affects people of all ages, although it is especially likely to strike the elderly. Joint discomfort, stiffness, soreness, and swelling are all signs of rheumatoid arthritis. At the moment, rheumatoid arthritis has no known cure. Nonsteroidal anti-inflammatory medications (NSAIDs), corticosteroids, disease-modifying anti-rheumatic medications (DMARDs), and uric acid medications are among the medications that are effectively used to manage the symptoms of rheumatoid arthritis.
- Biocon Biologics Ltd., a division of Biocon Ltd., declared in July 2023 that HULIO (adalimumab-fkjp) injectable, a biosimilar to Humira (adalimumab), would be available in the United States for the management of rheumatoid arthritis.
- Pfizer Inc. stated in February 2022 that the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb), an interchangeable biosimilar to Humira (adalimumab), has been accepted for consideration by the U.S. Food and Drug Administration (FDA).
- A commercialization and license agreement was signed in February 2022 by Biogen Inc. and Xbrane Biopharma AB for the development, production, and marketing of Xcimzane, a preclinical monoclonal antibody that is a potential biosimilar to CIMZIA (certolizumab pegol).
Market Opportunities and Challenges
The rise in rheumatoid arthritis prevalence, the rise in demand for rheumatoid arthritis drugs, the expiration of patents and the introduction of biosimilar drugs, the aging of the population, the increase in the use of conventional DMARDs, and government campaigns to increase awareness of rheumatoid arthritis symptoms are the main factors propelling the growth of the rheumatoid arthritis drugs market. Other factors that support market expansion include advancements in advanced biologics, an increase in healthcare spending, a rise in purchasing power, and the availability of high-quality medications to middle-class and lower-class families worldwide. Conversely, during the projected period, the market for rheumatoid arthritis medications is expected to have strong growth potential due to increased awareness of the need of early detection and treatment of rheumatoid arthritis.
The availability of natural treatments for rheumatoid arthritis and non-drug pain management methods would impede the market's recent expansion and development. Acupuncture, Tai-chi, and other natural therapies are becoming more and more well-liked in society. Acupuncture is quickly making a name for itself as a common pain therapy, according to studies. Numerous ailments, such as fibromyalgia, arthritis, back pain, sprains, and sports-related injuries, can be treated with acupuncture. An ancient martial practice called tai-chi is beneficial in managing rheumatoid arthritis. Deep breathing and slow, soft motions are key components in tai chi. Furthermore, applying topical creams, lotions, and gels directly to the skin can assist relieve discomfort.
Market Competitive Landscape
There are a number of significant businesses in the competitive and fragmented rheumatoid arthritis drug industry. AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc, Pfizer Inc, Novartis AG, Sanofi S.A, F. Hoffmann-La Roche Ltd, Merck & Co, Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company are a few of the top companies in the sector.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc, Pfizer Inc, Novartis AG, Sanofi S.A, F. Hoffmann-La Roche Ltd, Merck & Co, Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company. |
COVID-19 Impact on Global Rheumatoid Arthritis Drugs Market
The COVID-19 epidemic was deemed a public health emergency of international concern by the World Health Organization (WHO) on January 30, 2020. Globally, COVID-19 has impacted almost 210 countries. Patients with rheumatoid arthritis who have COVID-19 infection may be more likely to experience severe symptoms and other problems, according to the Lancet Rheumatology 2020. Certain DMARDs, including the medication hydroxychloroquine, are frequently used to treat rheumatoid arthritis, and they are being studied as possible COVID-19 therapies. Additionally, patients with COVID-19 are being evaluated for other commonly used treatments such biologics that target interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra). Consequently, during the anticipated period, the COVID-19 infection increased growth potential for producers of medications for rheumatoid arthritis.
Key Target Audience:
- Pharmaceutical Drug Manufacturer
- Rheumatoid Arthritis Treatment Centers
- Research and Development (R&D) Companies
- Government Research Laboratories
- Government Authorities and R&D Institutions
- Academic & Medical Research Institutions
Our in-depth analysis of the Rheumatoid Arthritis Drugs Market includes the following segments:
| By Drug Class Type: |
|
| By Route of Administration: |
|
| By Sales Channel: |
|
| By Distribution Channel: |
|
Key Topics Covered in the Report:
- Global Rheumatoid Arthritis Drugs Market Size (FY’2024-FY’2033)
- Overview of Global Rheumatoid Arthritis Drugs Market
- Segmentation of Global Rheumatoid Arthritis Drugs Market By Drug Class Type (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others)
- Segmentation of Global Rheumatoid Arthritis Drugs Market By Route of Administration (Oral, Parenteral)
- Segmentation of Global Rheumatoid Arthritis Drugs Market By Sales Channel (Prescription-based Drugs, Over-the-counter Drugs)
- Segmentation of Global Rheumatoid Arthritis Drugs Market By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- Statistical Snap of Global Rheumatoid Arthritis Drugs Market
- Expansion Analysis of Global Rheumatoid Arthritis Drugs Market
- Problems and Obstacles in Global Rheumatoid Arthritis Drugs Market
- Competitive Landscape in the Global Rheumatoid Arthritis Drugs Market
- Impact of COVID-19 and Demonetization on Global Rheumatoid Arthritis Drugs Market
- Details on Current Investment in Global Rheumatoid Arthritis Drugs Market
- Competitive Analysis of Global Rheumatoid Arthritis Drugs Market
- Prominent Players in the Global Rheumatoid Arthritis Drugs Market
- SWOT Analysis of Global Rheumatoid Arthritis Drugs Market
- Global Rheumatoid Arthritis Drugs Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Global Rheumatoid Arthritis Drugs Market
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Rheumatoid Arthritis Drugs Market Manufacturing Base Distribution, Sales Area, Ingredients6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Rheumatoid Arthritis Drugs Market
7. Global Rheumatoid Arthritis Drugs Market, By Drug Class Type (USD Million) 2020-2033
7.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2020-20267.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2027-20337.3. Disease-modifying Anti-Rheumatic Drugs (DMARDs)7.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)7.5. Corticosteroids7.6. Uric Acid Drugs7.7. Others
8. Global Rheumatoid Arthritis Drugs Market, By Route of Administration (USD Million) 2020-2033
8.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2020-20268.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2027-20338.3. Oral8.4. Parenteral
9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel (USD Million) 2020-2033
9.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2020-20269.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2027-20339.3. Prescription-based Drugs9.4. Over-the-counter Drugs
10. Global Rheumatoid Arthritis Drugs Market, By Distribution Channel (USD Million) 2020-2033
10.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2020-202610.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2027-203310.3. Hospital Pharmacy10.4. Retail Pharmacy10.5. Online Pharmacy
11. Global Rheumatoid Arthritis Drugs Market, Forecast, 2020-2033 (USD Million)
11.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share
12. Global Rheumatoid Arthritis Drugs Market, By Region, 2020-2033 (USD Million)
12.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2020-2026)12.2. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2027-2033)12.3. Asia-Pacific12.3.1. Australia12.3.2. China12.3.3. India12.3.4. Japan12.3.5. South Korea12.3.6. Rest of Asia-Pacific12.4. Europe12.4.1. France12.4.2. Germany12.4.3. Italy12.4.4. Spain12.4.5. United Kingdom12.4.6. Rest of Europe12.5. Middle East and Africa12.5.1. Kingdom of Saudi Arabia12.5.2. United Arab Emirates12.5.3. Qatar12.5.4. South Africa12.5.5. Egypt12.5.6. Morocco12.5.7. Nigeria12.5.8. Rest of Middle-East and Africa12.6. North America12.6.1. Canada12.6.2. Mexico12.6.3. United States12.7. Latin America12.7.1. Argentina12.7.2. Brazil12.7.3. Rest of Latin America
13. Company Profile
13.1. AbbVie Inc.13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments13.2. Johnson & Johnson Innovative Medicine13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments13.3. Amgen Inc.13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments13.4. Pfizer Inc.13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments13.5. Novartis AG13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments13.6. Sanofi S.A.13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments13.7. F. Hoffmann-La Roche Ltd.13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments13.8. Merck & Co., Inc.13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments13.9. Bristol-Myers Squibb Company13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments13.10. Eli Lilly and Company13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments13.11. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Rheumatoid Arthritis Drugs Market CAGR of 3.8% during the forecast period.
You can get the sample pages by clicking the link -Click Here
Rheumatoid Arthritis Drugs Market size is USD 78718.42 million from 2024 to 2033.
Rheumatoid Arthritis Drugs Market Segment is Covered By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel
The North America region is anticipated to have the highest market share in Rheumatoid Arthritis Drugs Market.
The key players in the market include Companies Covered Brother Industries, D. Gen, Dover Corporation, Konica Minolta, Kornit Digital, Mimaki Engineering, Robustelli, RolandDG Corporation, Seiko Epson, SPGPrints, and others.
The availability of natural treatments for rheumatoid arthritis and non-drug pain management methods would impede the market's recent expansion and development.
Rheumatoid Arthritis Drugs Market is projected to reach USD 78718.42 million by 2033, growing at a CAGR of 3.8% during the forecast period.
Rheumatoid Arthritis Drugs Market grew in market size from 2024. The Market is expected to reach USD 78718.42 million by 2033, at a CAGR of 3.8% during the forecast period.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
